COVID-19's hidden toll on liver cancer patients revealed
NCT ID NCT04367805
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how COVID-19 impacts people with hepatocellular carcinoma, a type of liver cancer. Researchers will track infection rates and see how the virus affects liver function, cancer treatment, and overall health. About 23 participants from a French national liver cancer registry are included. The goal is to better understand risks and outcomes for this vulnerable group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Amiens
Amiens, 80480, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Could a vaccine help fight Hard-to-Treat cancers?